BioCentury
ARTICLE | Finance

2Q13 Financial Markets Preview: Manning the middle

Biotech 2Q13: Buysiders pick Orphan, cancer plays; big names to lose steam

April 1, 2013 7:00 AM UTC

Buysiders are being drawn to mid- and small cap biotechs with solid balance sheets and/or near-term inflection points going into 2Q13, a period that may be relatively quiet for some of the sector's largest names.

The challenging environment for illiquid micro-caps seems likely to persist, though investors chasing returns will inevitably take some fliers on smaller names...